Hepatocellular Carcinoma

The FDA has granted orphan drug designation for the treatment of patients with hepatocellular carcinoma.

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

Alan P. Venook, MD, highlights notable NCCN guideline updates in HCC, considerations for implementing the changes in the clinic, and next steps in HCC.

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.

An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

The EMA has granted orphan medicinal product designation to rivoceranib plus camrelizumab in first-line unresectable hepatocellular carcinoma.

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.

The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.

Elevar Therapeutics plans to resubmit a new drug application for rivoceranib plus camrelizumab for first-line unresectable hepatocellular carcinoma.

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.

Anthony B. El-Khoueiry, MD, on data for regorafenib plus pembrolizumab in pretreated advanced hepatocellular carcinoma.

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC.